All Stories

  1. Human Enhancement Drugs

    Article • November 2025, Taylor & Francis

    Jim McVeigh

  2. Reflecting on the current human enhancement drugs categorisation and new directions to consider

    Article • November 2025, Taylor & Francis

    Jim McVeigh

  3. Thinking in systems to understand and respond to harmful AAS use

    Article • November 2025, Taylor & Francis

    Jim McVeigh

  4. “Dropping off the edge of a cliff”

    Article • November 2025, Taylor & Francis

    Jim McVeigh

  5. “Big-blast, little-blast”: Risk neutralization strategies for sustaining masculinity by older men who use anabolic androgenic steroids (OMAAS)

    Article • Performance Enhancement & Health, October 2025, Elsevier

    Jim McVeigh

  6. The material practices and social dimensions of community care among people who use, produce, and supply image and performance enhancing drugs

    Article • Addiction Research & Theory, March 2025, Taylor & Francis

    Jim McVeigh

  7. Quantification and identification of pharmacological and psychological components of the androgen withdrawal syndrome in men: a community-dwelling cross-sectional study

    Article • Endocrine Abstracts, February 2025, Bioscientifica

    Jim McVeigh

  8. Off-label use of clomiphene citrate to treat anabolic androgenic steroid induced hypogonadism upon cessation among men (CloTASH) – A pilot study protocol

    Article • MethodsX, December 2024, Elsevier

    Jim McVeigh

  9. “I would never go to the doctor and speak about steroids”: Anabolic androgenic steroids, stigma and harm

    Article • Drugs Education Prevention and Policy, July 2024, Taylor & Francis

    Jim McVeigh

  10. “You Could Try This Compound, but it Might Send You nuts”: How Steroid Suppliers Perceive the Underground Market and Their ‘Hybrid’ Role within It

    Article • Deviant Behavior, July 2024, Taylor & Francis

    Jim McVeigh

  11. The Association Between the Nonmedical use of Anabolic–Androgenic Steroids and Interpersonal Violence: A Meta-Analysis

    Article • Trauma Violence & Abuse, July 2023, SAGE Publications

    Jim McVeigh

  12. Internet sourcing and unsafe use of controlled drugs (opioids, sedatives and GABA drugs) in the UK: An in depth case study of consumer dynamics during COVID-19

    Article • Emerging Trends in Drugs Addictions and Health, January 2023, Elsevier

    Jim McVeigh

  13. ‘Sustaining masculinity’: a scoping review of anabolic androgenic steroid use by older males

    Article • Drugs Education Prevention and Policy, November 2022, Taylor & Francis

    Jim McVeigh

  14. Systems mapping to understand complexity in the association between image and performance enhancing drugs (IPEDs) and harm

    Article • International Journal of Drug Policy, September 2022, Elsevier

    Jim McVeigh

  15. Anabolic androgenic steroid use population size estimation: a first stage study utilising a Delphi exercise

    Article • Drugs Education Prevention and Policy, May 2022, Taylor & Francis

    Jim McVeigh

  16. Severity of anabolic steroid dependence, executive function, and personality traits in substance use disorder patients in Norway

    Article • Drug and Alcohol Dependence, February 2022, Elsevier

    Jim McVeigh

  17. Generating evidence on the use of Image and performance enhancing drugs in the UK: results from a scoping review and expert consultation by the Anabolic Steroid UK network

    Article • Harm Reduction Journal, October 2021, Springer Science + Business Media

    Jim McVeigh

  18. Harm reduction strategies for androgen users

    Article • Current Opinion in Endocrinology Diabetes and Obesity, September 2021, Wolters Kluwer Health

    Jim McVeigh

  19. Human enhancement drugs: Emerging issues and responses

    Article • International Journal of Drug Policy, September 2021, Elsevier

    Jim McVeigh

  20. A Scoping Review of Non-Medical and Extra-Medical Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

    Article • Drug Safety, July 2021, Springer Science + Business Media

    Jim McVeigh

  21. Anabolic-androgenic steroid administration increases self-reported aggression in healthy males: a systematic review and meta-analysis of experimental studies

    Article • Psychopharmacology, March 2021, Springer Science + Business Media

    Jim McVeigh

  22. Looking Beyond the Provision of Injecting Equipment to People Who Use Anabolic Androgenic Steroids: Harm Reduction and Behavior Change Goals for UK Policy

    Article • Contemporary Drug Problems, March 2021, SAGE Publications

    Jim McVeigh

  23. “A slippery slope”: a scoping review of the self-injection of unlicensed oils and fillers as body enhancement

    Article • Performance Enhancement & Health, February 2021, Elsevier

    Jim McVeigh

  24. Internet sourcing and UK end consumer trend interest in the controlled medicines (opioids, sedatives and GABA drugs) in pre and post COVID-19 timeframes

    Article • Emerging Trends in Drugs Addictions and Health, January 2021, Elsevier

    Jim McVeigh

  25. How the love of muscle can break a heart: Impact of anabolic androgenic steroids on skeletal muscle hypertrophy, metabolic and cardiovascular health

    Article • Reviews in Endocrine and Metabolic Disorders, December 2020, Springer Science + Business Media

    Jim McVeigh

  26. Factors associated with hepatitis C and HIV testing uptake among men who inject image and performance enhancing drugs

    Article • Drug and Alcohol Review, November 2020, Wiley

    Jim McVeigh

  27. 2,4 dinitrophenol: It's not just for men

    Article • International Journal of Drug Policy, October 2020, Elsevier

    Jim McVeigh

  28. Monitoring the use of drugs in bodybuilding: a novel drugs early warning system

    Article • International Journal of Drug Policy, September 2020, Elsevier

    Jim McVeigh

  29. Perspectives of Frontline Professionals on Palestinian Children Living with Sibling and Parental Drug Use in the UNRWA Camps, Jordan

    Article • International Journal of Mental Health and Addiction, June 2020, Springer Science + Business Media

    Jim McVeigh

  30. Motives and Correlates of Anabolic-Androgenic Steroid Use With Stimulant Polypharmacy

    Article • Contemporary Drug Problems, April 2020, SAGE Publications

    Jim McVeigh

  31. Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Men Who Have Sex with Men (MSM): A Scoping Review on PrEP Service Delivery and Programming

    Article • AIDS and Behavior, April 2020, Springer Science + Business Media

    Jim McVeigh

  32. Anabolic-Androgenic Steroid Use in the Eastern Mediterranean Region: a Scoping Review of Extant Empirical Literature

    Article • International Journal of Mental Health and Addiction, January 2020, Springer Science + Business Media

    Jim McVeigh

  33. The Anabolic Androgenic Steroid Treatment Gap: A National Study of Substance Use Disorder Treatment

    Article • Substance Abuse Research and Treatment, January 2020, SAGE Publications

    Jim McVeigh

  34. Treatments for people who use anabolic androgenic steroids: a scoping review

    Article • Harm Reduction Journal, December 2019, Springer Science + Business Media

    Jim McVeigh

  35. Engaging with people who use image and performance enhancing drugs: One size does not fit all

    Article • International Journal of Drug Policy, September 2019, Elsevier

    Jim McVeigh

  36. Perspectives of Frontline Professionals on Palestinian Children Living with Sibling and Parental Drug Use in the West Bank and Gaza Strip

    Article • International Journal of Mental Health and Addiction, August 2019, Springer Science + Business Media

    Jim McVeigh

  37. Commentary: Steroid Madness- has the dark side of anabolic-androgenic steroids (AAS) been over-stated?

    Article • Performance Enhancement & Health, June 2019, Elsevier

    Jim McVeigh

  38. The modes of administration of anabolic-androgenic steroid (AAS) users: are non-injecting people who use steroids overlooked?

    Article • Drugs Education Prevention and Policy, May 2019, Taylor & Francis

    Jim McVeigh

  39. Palestinian Children’s Experiences of Drug Abuse in the Home in the Occupied Territories of Palestine: a Scoping Review of Extant Literature

    Article • International Journal of Mental Health and Addiction, April 2019, Springer Science + Business Media

    Jim McVeigh

  40. Secondary distribution of injecting equipment obtained from needle and syringe programmes by people injecting image and performance enhancing drugs: England and Wales, 2012-15

    Article • Drug and Alcohol Dependence, February 2019, Elsevier

    Jim McVeigh

  41. An evidence-based socioecological framework to understand men’s use of anabolic androgenic steroids and inform interventions in this area

    Article • Drugs Education Prevention and Policy, July 2018, Taylor & Francis

    Jim McVeigh

  42. Identifying a typology of men who use anabolic androgenic steroids (AAS)

    Article • International Journal of Drug Policy, May 2018, Elsevier

    Jim McVeigh

  43. A systematic review investigating the behaviour change strategies in interventions to prevent misuse of anabolic steroids

    Article • Journal of Health Psychology, November 2017, SAGE Publications

    Jim McVeigh

  44. Low levels of hepatitis C diagnosis and testing uptake among people who inject image and performance enhancing drugs in England and Wales, 2012-15

    Article • Drug and Alcohol Dependence, October 2017, Elsevier

    Jim McVeigh

  45. Community pharmacist experiences of providing needle and syringe programmes in Ireland

    Article • Research in Social and Administrative Pharmacy, July 2017, Elsevier

    Jim McVeigh

  46. Adverse Effects, Health Service Engagement, and Service Satisfaction Among Anabolic Androgenic Steroid Users

    Article • Contemporary Drug Problems, March 2017, SAGE Publications

    Jim McVeigh

  47. Anabolic steroids in the UK: an increasing issue for public health

    Article • Drugs Education Prevention and Policy, November 2016, Taylor & Francis

    Jim McVeigh

  48. 2,4-Dinitrophenol, the inferno drug: a netnographic study of user experiences in the quest for leanness

    Article • Journal of Substance Use, May 2016, Taylor & Francis

    Jim McVeigh

  49. Access to needle and syringe programs by people who inject image and performance enhancing drugs

    Article • International Journal of Drug Policy, May 2016, Elsevier

    Jim McVeigh

  50. A scoping review of home-produced heroin and amphetamine-type stimulant substitutes: implications for prevention, treatment, and policy

    Article • Harm Reduction Journal, April 2016, Springer Science + Business Media

    Jim McVeigh

  51. Harm reduction interventions should encompass people who inject image and performance enhancing drugs

    Article • BMJ, April 2016, BMJ

    Jim McVeigh

  52. Risk of HIV and Hepatitis B and C Over Time Among Men Who Inject Image and Performance Enhancing Drugs in England and Wales

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, March 2016, Wolters Kluwer Health

    Jim McVeigh

  53. Polypharmacy among anabolic-androgenic steroid users: a descriptive metasynthesis

    Article • Substance Abuse Treatment Prevention and Policy, March 2015, Springer Science + Business Media

    Jim McVeigh

  54. Synthetic growth hormone releasers detected in seized drugs: new trends in the use of drugs for performance enhancement

    Article • Addiction, January 2015, Wiley

    Jim McVeigh

  55. Anabolic steroids detected in bodybuilding dietary supplements - a significant risk to public health

    Article • Drug Testing and Analysis, October 2014, Wiley

    Jim McVeigh

  56. Environments, risk and health harms: a qualitative investigation into the illicit use of anabolic steroids among people using harm reduction services in the UK

    Article • BMJ Open, June 2014, BMJ

    Jim McVeigh

  57. The composition of anabolic steroids from the illicit market is largely unknown: implications for clinical case reports

    Article • QJM, May 2014, Oxford University Press (OUP)

    Jim McVeigh

  58. Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet

    Article • Drug Testing and Analysis, April 2014, Wiley

    Jim McVeigh

  59. Injection site infections and injuries in men who inject image- and performance-enhancing drugs: prevalence, risks factors, and healthcare seeking

    Article • Epidemiology and Infection, April 2014, Cambridge University Press

    Jim McVeigh

  60. Online marketing of synthetic peptide hormones: poor manufacturing, user safety, and challenges to public health

    Article • Drug Testing and Analysis, March 2014, Wiley

    Jim McVeigh

  61. Views and experiences of hepatitis C testing and diagnosis among people who inject drugs: Systematic review of qualitative research

    Article • International Journal of Drug Policy, March 2014, Elsevier

    Jim McVeigh

  62. Is the breast cancer drug tamoxifen being sold as a bodybuilding dietary supplement?

    Article • BMJ, February 2014, BMJ

    Jim McVeigh

  63. Variability and dilemmas in harm reduction for anabolic steroid users in the UK: a multi-area interview study

    Article • Harm Reduction Journal, January 2014, Springer Science + Business Media

    Jim McVeigh

  64. Effectiveness of interventions to increase hepatitis C testing uptake among high-risk groups: a systematic review

    Article • European Journal of Public Health, October 2013, Oxford University Press (OUP)

    Jim McVeigh

  65. Prevalence of, and risk factors for, HIV, hepatitis B and C infections among men who inject image and performance enhancing drugs: a cross-sectional study

    Article • BMJ Open, September 2013, BMJ

    Jim McVeigh

  66. Epidemiology of Use of Novel Psychoactive Substances

    Article • January 2013, Elsevier

    Jim McVeigh

  67. Drogas potenciadoras para la búsqueda de la perfección

    Article • Adicciones, September 2012, Socidrogalcohol

    Jim McVeigh

  68. Drogas potenciadoras para la búsqueda de la perfección

    Article • Adicciones, September 2012, Socidrogalcohol

    Jim McVeigh

  69. Social, policy, and public health perspectives on new psychoactive substances

    Article • Drug Testing and Analysis, July 2011, Wiley

    Jim McVeigh

  70. Should "legal highs" be regulated as medicinal products?

    Article • BMJ, February 2011, BMJ

    Jim McVeigh

  71. Next generation challenges: An overview of harm reduction 2010, IHRA's 21st conference

    Article • International Journal of Drug Policy, January 2011, Elsevier

    Jim McVeigh

  72. Adulterants in illicit drugs: a review of empirical evidence

    Article • Drug Testing and Analysis, December 2010, Wiley

    Jim McVeigh

  73. Meeting the health needs of problematic drug users through community pharmacy: A qualitative study

    Article • Journal of Substance Use, September 2010, Taylor & Francis

    Jim McVeigh

  74. Older and sicker: Changing mortality of drug users in treatment in the North West of England

    Article • International Journal of Drug Policy, September 2010, Elsevier

    Jim McVeigh

  75. Optimal provision of needle and syringe programmes for injecting drug users: A systematic review

    Article • International Journal of Drug Policy, September 2010, Elsevier

    Jim McVeigh

  76. Injecting human growth hormone as a performance-enhancing drug—perspectives from the United Kingdom

    Article • Journal of Substance Use, October 2009, Taylor & Francis

    Jim McVeigh

  77. Integrating Drug-Related Monitoring Systems—An Intelligence Led Approach

    Article • Contemporary Drug Problems, September 2009, SAGE Publications

    Jim McVeigh

  78. Elephant in the room? The methodological implications for public health research of performance-enhancing drugs derived from the illicit market

    Article • Drug Testing and Analysis, July 2009, Wiley

    Jim McVeigh

  79. Use of melanotan I and II in the general population

    Article • BMJ, February 2009, BMJ

    Jim McVeigh

  80. The dire consequences of doping?

    Article • The Lancet, November 2008, Elsevier

    Jim McVeigh

  81. Diversion and abuse of methylphenidate in light of new guidance

    Article • BMJ, October 2008, BMJ

    Jim McVeigh

  82. The Involvement of Drugs and Alcohol in Drug-Facilitated Sexual Assault

    Article • Trauma Violence & Abuse, July 2008, SAGE Publications

    Jim McVeigh

  83. Problematic drug use, ageing and older people: trends in the age of drug users in northwest England

    Article • Ageing and Society, October 2007, Cambridge University Press

    Jim McVeigh

  84. The impact of citrate introduction at UK syringe exchange programmes: a retrospective cohort study in Cheshire and Merseyside, UK

    Article • Harm Reduction Journal, January 2007, Springer Science + Business Media

    Jim McVeigh

  85. The role of substance use in non‐drug related deaths: a cross‐sectional study of drug treatment clients in the North West of England

    Article • Journal of Substance Use, January 2007, Taylor & Francis

    Jim McVeigh

  86. DRINK DETECTIVE: COMMENTS ON THE MANUFACTURER'S RESPONSE

    Article • Addiction, October 2006, Wiley

    Jim McVeigh

  87. The ability of two commercially available quick test kits to detect drug-facilitated sexual assault drugs in beverages

    Article • Addiction, October 2006, Wiley

    Jim McVeigh

  88. Trends in drop out, drug free discharge and rates of re-presentation: a retrospective cohort study of drug treatment clients in the North West of England

    Article • BMC Public Health, August 2006, Springer Science + Business Media

    Jim McVeigh

  89. Crack-cocaine injection: A retrospective analysis of clients in Merseyside specialist drug treatment agencies

    Article • Drugs Education Prevention and Policy, June 2005, Taylor & Francis

    Jim McVeigh

  90. Effects of nightlife activity on health

    Article • Nursing Standard, April 2005, RCNi

    Jim McVeigh

  91. Effects of nightlife activity on health

    Article • Nursing Standard, April 2005, RCNi

    Jim McVeigh

  92. A potent cocktail

    Article • Nursing Standard, August 2004, RCNi

    Jim McVeigh

  93. New challenges for agency based syringe exchange schemes: analysis of 11 years of data (1991–2001) in Merseyside and Cheshire, United Kingdom

    Article • International Journal of Drug Policy, December 2003, Elsevier

    Jim McVeigh

  94. Predictors of hepatitis B and C infection in injecting drug users both in and out of drug treatment

    Article • Addiction, December 2001, Wiley

    Jim McVeigh

  95. Water usage reduction in a semiconductor fabricator

    Article • Institute of Electrical & Electronics Engineers (IEEE)

    Jim McVeigh